Rigel Pharmaceuticals (RIGL) Expected to Release Quarterly Earnings on Tuesday

Key Points

• Rigel Pharmaceuticals is expected to report Q3 2026 results after the market closes on November 3. Analysts forecast earnings of $0.921 per share and revenue of $80.10 million.
• In the prior quarter, Rigel reported $0.88 EPS and $78.70 million in revenue, exceeding analyst expectations of $0.09 EPS and $55.27 million in revenue.
• Shares recently traded at $49.91, up 3.7%, while analysts maintain a consensus Hold rating with an average price target of $59.00; ratings range from Strong Sell to Buy.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of $0.9210 per share and revenue of $80.10 million for the quarter. Individuals are encouraged to explore the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Rigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.88 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.79. Rigel Pharmaceuticals had a net margin of 116.30% and a return on equity of 22.95%. The firm had revenue of $78.70 million during the quarter, compared to analysts' expectations of $55.27 million. On average, analysts expect Rigel Pharmaceuticals to post $2.98 EPS for the current fiscal year and $4.32 EPS for the next fiscal year.

Rigel Pharmaceuticals Trading Up 3.7%

Shares of NASDAQ RIGL opened at $49.91 on Tuesday. The stock has a market capitalization of $923.33 million, a PE ratio of 3.06 and a beta of 1.19. The stock has a fifty day simple moving average of $47.18 and a 200-day simple moving average of $37.08. Rigel Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $52.24.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RIGL. Weiss Ratings upgraded Rigel Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. Piper Sandler reaffirmed a "neutral" rating and issued a $49.00 target price (up from $40.00) on shares of Rigel Pharmaceuticals in a research note on Monday, August 17th. Citigroup reaffirmed a "buy" rating on shares of Rigel Pharmaceuticals in a research note on Thursday, August 6th. HC Wainwright restated a "buy" rating and issued a $85.00 target price on shares of Rigel Pharmaceuticals in a report on Monday, October 19th. Finally, Zacks Research downgraded Rigel Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Wednesday, October 14th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $59.00.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc NASDAQ: RIGL is a biotechnology company focused on developing and commercializing therapies for hematologic diseases, cancer and immune-related disorders. Founded in 1996 and headquartered in South San Francisco, California, the company uses small-molecule drug discovery and kinase biology to develop medicines that address unmet medical needs.

Rigel's primary commercial product is Tavalisse (fostamatinib disodium), an oral spleen tyrosine kinase inhibitor approved in the United States for treating thrombocytopenia in adults with chronic immune thrombocytopenia who have had an insufficient response to previous treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.